GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Zhong Yuan Bio-Technology Holdings Ltd (OTCPK:ZHYBF) » Definitions » Operating Income

Zhong Yuan Bio-Technology Holdings (Zhong Yuan Bio-Technology Holdings) Operating Income : $-0.27 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Zhong Yuan Bio-Technology Holdings Operating Income?

Zhong Yuan Bio-Technology Holdings's Operating Income for the six months ended in Sep. 2023 was $0.49 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.27 Mil.

Warning Sign:

Zhong Yuan Bio-Technology Holdings Ltd has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Zhong Yuan Bio-Technology Holdings's Operating Income for the six months ended in Sep. 2023 was $0.49 Mil. Zhong Yuan Bio-Technology Holdings's Revenue for the six months ended in Sep. 2023 was $1.58 Mil. Therefore, Zhong Yuan Bio-Technology Holdings's Operating Margin % for the quarter that ended in Sep. 2023 was 31.01%.

Zhong Yuan Bio-Technology Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zhong Yuan Bio-Technology Holdings's annualized ROC % for the quarter that ended in Sep. 2023 was 35.75%. Zhong Yuan Bio-Technology Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 78.67%.


Zhong Yuan Bio-Technology Holdings Operating Income Historical Data

The historical data trend for Zhong Yuan Bio-Technology Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhong Yuan Bio-Technology Holdings Operating Income Chart

Zhong Yuan Bio-Technology Holdings Annual Data
Trend Dec16 Dec17 Dec18 Mar19 Mar20 Mar21 Mar22 Mar23
Operating Income
Get a 7-Day Free Trial 0.31 -0.09 -0.02 -0.64 -1.20

Zhong Yuan Bio-Technology Holdings Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.33 -0.44 -0.76 0.49

Zhong Yuan Bio-Technology Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhong Yuan Bio-Technology Holdings  (OTCPK:ZHYBF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zhong Yuan Bio-Technology Holdings's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=0.98 * ( 1 - -0.23% )/( (2.629 + 2.866)/ 2 )
=0.982254/2.7475
=35.75 %

where

Note: The Operating Income data used here is two times the semi-annual (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Zhong Yuan Bio-Technology Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.972/( ( (0.518 + max(0.188, 0)) + (0.636 + max(1.129, 0)) )/ 2 )
=0.972/( ( 0.706 + 1.765 )/ 2 )
=0.972/1.2355
=78.67 %

where Working Capital is:

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.354 + 0.131 + 0.28) - (0.466 + 0.11 + 0.0010000000000003)
=0.188

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.059 + 0.086 + 0.65) - (0.666 + 0 + 0)
=1.129

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Zhong Yuan Bio-Technology Holdings's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=0.49/1.58
=31.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Zhong Yuan Bio-Technology Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of Zhong Yuan Bio-Technology Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhong Yuan Bio-Technology Holdings (Zhong Yuan Bio-Technology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
28 Queen’s Road East, Suite 901, Tesbury Centre, Wanchai, Hong Kong, HKG
Zhong Yuan Bio-Technology Holdings Ltd is engaged in the business of developing and marketing nervonic acid-based health supplements and sales of acer truncatum seedlings. The company has two reportable segments such as sales of health care supplements and technical supporting services. The company generates its revenue primarily from the sales of health care supplements.
Executives
Tingting Chang director, 10 percent owner, officer: CEO RM 1002, 10THFL, LONG HU FUTURE OFFICE, NO. 1 EAST SHI LI PU ROAD, CHAO YANG DISTRICT, BEIJING F4 100024
James M Cassidy director, 10 percent owner, officer: president,secretary,treasurer 215 APOLENA AVENUE, NEWPORT BEACH CA 92662
James K Mckillop director, 10 percent owner, officer: Vice President 9454 WILSHIRE BOULEVARD, SUITE 612, BEVERLY HILLS CA 90212

Zhong Yuan Bio-Technology Holdings (Zhong Yuan Bio-Technology Holdings) Headlines

No Headlines